News

Latest news

2019-04-02	ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
2019-03-28	ContextVision signs agreement for research based on unique big data cohorts
2019-03-27	ContextVision - Fredrik Palm appointed new CEO

2019-04-02	ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
2019-03-28	ContextVision signs agreement for research based on unique big data cohorts
2019-03-27	ContextVision - Fredrik Palm appointed new CEO

2019-04-02 Meet us at AIUM, 6 - 10 April, 2019
2019-02-18 Meet us at ICE, Feb 17–19, 2019
2019-02-04 Visit ContextVision at ECR 2019, booth 111 (Expo X1) to see the latest in image enhancement

2019-04-02 Meet us at AIUM, 6 - 10 April, 2019
2019-02-18 Meet us at ICE, Feb 17–19, 2019
2019-02-04 Visit ContextVision at ECR 2019, booth 111 (Expo X1) to see the latest in image enhancement

2019-03-18	Lovende svar i ContextVision studie - appearance in the Norwegian business newspaper Finansavisen
2018-12-07	ContextVision Introduces AI-Powered Image Enhancement for Digital Radiography
2018-06-26	Digital pathology solution could speed up prostate cancer diagnosis

2019-03-18	Lovende svar i ContextVision studie - appearance in the Norwegian business newspaper Finansavisen
2018-12-07	ContextVision Introduces AI-Powered Image Enhancement for Digital Radiography
2018-06-26	Digital pathology solution could speed up prostate cancer diagnosis

ContextVision Company Presentation (pdf)

Ultrasound Product Brochure (pdf)

Digital Radiography Product Brochure (pdf)

Mammography Product Brochure (pdf)

MRI Product Brochure (pdf)

For press information and/or inquiries, please contact

Fredrik Palm, CEO

ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. As the global market leader within image enhancement, ContextVision is a software partner to leading medical imaging manufacturers around the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision has developed state-of-the-art capabilities in the latest artificial intelligence technologies. By combining these with its well-established GOP technology, the company is introducing a new generation of image enhancement products. ContextVision is also approaching the growing digital pathology market with new AI-based decision support tools for pathologists.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.